Today: 29 June 2026
Browse Category

Pharmaceutical News 22 December 2025 - 1 June 2026

Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Inc shares gained in early U.S. premarket trading Monday after late-stage trial results reported its experimental pill for pancreatic cancer almost doubled survival against chemo. RVMD was last seen at $157.48, up $2.93, or 1.9%, ahead of the regular Nasdaq open. The company’s market cap hovered at about $31.2 billion. Nasdaq’s 2026 calendar does not list June 1 as a holiday—Memorial Day shows May 25 and Juneteenth June 19 as closures. Revolution announced the Phase 3 RASolute 302 data on Sunday at the American Society of Clinical Oncology meeting, saying the results hit the New England Journal of Medicine that same day. The timing gave investors a deeper look at the data driving the stock since the top-line update in April.
1 June 2026
···
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Pharmaceuticals is off the Nasdaq tape now that Biogen has finished its buyout. The focus moves to Biogen and if it can pull enough revenue from Syfovre and Empaveli to make the acquisition pay. APLS shares aren’t in the public’s hands anymore. Investors got $41 in cash per share plus a CVR tied to sales of Syfovre, Apellis’ drug for geographic atrophy, a type of advanced dry macular degeneration. The CVR could pay more if certain sales goals are met. Biogen said Apellis is now a wholly owned unit. Apellis shares stopped trading on Nasdaq after the deal closed.
20 May 2026
····
Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharmaceuticals Holding Corp. on Friday shared new data for its experimental Lyme disease antibody TNX-4800. The company said computer modeling from its Phase 1 study supports using two doses ahead of a planned field study in 2027. Tonix, based in Berkeley Heights, New Jersey, reported results at the Global Lyme Alliance. The company said these results tie to a planned adaptive Phase 2 field trial, which could start in the first half of 2027 if Tonix and the U.S. Food and Drug Administration agree. In an adaptive trial, rules let the design change as new data come in.
15 May 2026
···
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

CAMBRIDGE, Mass., May 6, 2026, 15:04 EDT Ernexa Therapeutics Inc. reported Wednesday that its lead cell therapy, ERNA-101, paired with PD-1 blockade, wiped out tumors completely and delivered 100% long-term survival in preclinical ovarian cancer studies. “Complete tumor eradication and durable survival,” is how Chief Scientific Officer Robert H. Pierce summed up the results. Chief Executive Sanjeev Luther called the data “beyond expectations.”
6 May 2026
···
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Inc. shares surged close to 16% Monday, after the Minneapolis-based biotech announced late Friday its lead drug candidate, gedatolisib, hit the primary endpoint in a late-stage breast cancer trial for patients with PIK3CA-mutant tumors. That news brought back attention to a July FDA decision and a planned cancer conference update in June for CELC stock. The immediate question: can this new data help expand the drug’s label? Back in January, Celcuity announced the FDA had accepted its New Drug Application for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer, put it on priority review, and penciled in July 17 as the target action date. HR+/HER2- refers to tumors fueled by hormone receptors that don’t express the HER2 protein; wild-type here means the PIK3CA gene hasn’t mutated.
4 May 2026
···
Edesa Biotech Stock Soars 54%: What’s Driving the ARDS Drug Rally Now

Edesa Biotech Stock Soars 54%: What’s Driving the ARDS Drug Rally Now

Edesa Biotech Inc. surged 53.9% to finish Monday at $11.17 on Nasdaq, after opening the day at $7.38 and reaching as high as $11.87. Trading volume spiked close to 9.0 million shares—a notable swing for the small clinical-stage biotech, especially considering its most recent company news release was nearly a month old. This shift is drawing attention as traders revisit Edesa’s respiratory data from February, just ahead of a pair of May presentations set for the American Thoracic Society meetings. On its news page, Edesa highlights a March 31 respiratory conference update and a March 26 release on vitiligo, with the Phase 3 paridiprubart announcement still marked as Feb. 24.
27 April 2026
·
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

CAMBRIDGE, Massachusetts, April 25, 2026, 12:07 Intellia Therapeutics is slated to release top-line results Monday from HAELO, its pivotal trial of lonvoguran ziclumeran—an experimental, one-and-done therapy aimed at hereditary angioedema. The company bills this as the first-ever Phase 3 data for an in vivo CRISPR gene-editing therapy, meaning the genetic tweak happens directly in the patient rather than in lab-modified cells.
25 April 2026
···
Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Health shares jumped in premarket trading Monday, following a Bloomberg News report that Novo Nordisk plans to offer its weight-loss drugs via the telehealth platform. An announcement confirming the partnership could come as early as Monday, marking a reversal from last month’s patent dispute between the two firms. Why does it matter now? Hims could soon have a more direct path to FDA-approved supply, right as Washington sharpens its focus on compounded GLP-1 drugs—the diabetes meds also used for weight loss. Compounding, making customized versions for individual patients, took off during recent shortages, but the FDA is tightening the screws.
9 March 2026
···
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

New York, Feb 24, 2026, 05:42 EST — Premarket Gossamer Bio shares hovered near $0.42 in premarket trading Tuesday, following a brutal 80% plunge the previous day after its flagship lung-disease therapy fell short in a late-stage trial. With the stock off about $1.71 from its earlier close, traders weighed a harder path to U.S. approval, despite some isolated positives in the data.
24 February 2026
···
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

New York, Jan 16, 2026, 12:51 PM EST — Regular session ImmunityBio shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded. The company said more than 85% of patients are enrolled in its QUILT-2.005 trial and it is targeting a U.S. filing by the end of 2026; an interim analysis showed 85% of patients on ANKTIVA plus BCG stayed in complete response at six months versus 57% on BCG alone and 84% versus 52% at nine months.
16 January 2026
···
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

New York, Jan 9, 2026, 11:52 EST — Regular session CG Oncology shares jumped on Friday after the company moved up the expected timing for late-stage trial results in bladder cancer. The stock was up 25.1% at $52.45 by 11:52 EST, versus Thursday’s close of $41.93, after trading between $41.63 and $52.64 on the day as volume topped 4.1 million shares.
9 January 2026
···
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

NEW YORK, December 30, 2025, 05:21 ET — Premarket Praxis Precision Medicines Inc shares rose 13.25% on Monday to close at $304.58, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its essential tremor candidate ulixacaltamide, a filing showed. The stock opened at $317.72 and traded between $298 and $317.72, and was down about 1% in after-hours trading. StockAnalysis+2SEC+2
30 December 2025
···
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. stock exchanges have not yet opened for the regular session. Nasdaq Edgewise Therapeutics, Inc. is in focus heading into the post-holiday session after the company delivered an encouraging clinical update for EDG-7500—its investigational therapy for hypertrophic cardiomyopathy—that helped drive a sharp rally in the last session before Christmas. PR Newswire
26 December 2025
···
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly and Company wrapped up a holiday-shortened Christmas Eve session with a modest gain — and then drifted slightly lower in thin after-hours trading as investors digested a policy-heavy news cycle around GLP‑1 obesity medicines. With U.S. markets closed on Christmas Day and set to reopen Friday, today’s late tape is less about big price swings and more about positioning: where Lilly stands in the global obesity market, what Washington’s latest coverage model could mean for pricing and volume, and what catalysts are coming next. AP News
24 December 2025
···
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual. On Monday, December 22, 2025, Gilead announced it has exercised its option to license Assembly Biosciences’ investigational herpes simplex virus programs—a move that strengthens Gilead’s long-term antiviral pipeline beyond HIV. The development lands just days after Gilead joined other major drugmakers in a Trump administration “most-favored-nation” drug-pricing agreement tied to tariff relief and direct-to-consumer drug access via TrumpRx.gov. Gilead+2Gilead+2
22 December 2025
·
1 2

Stock Market Today

  • SpaceX (SPCX) shares fade after IPO pop; attention turns to Nasdaq-100 inclusion
    June 29, 2026, 1:43 PM EDT. SpaceX (NASDAQ: SPCX) jumped as high as $225 from its $135 IPO, but slipped back to near $155. The company is still losing cash even with $4.7 billion Q1 2026 revenue. Some see index funds as forced buyers if SPCX gets added to the Nasdaq-100, which could bring new demand and help counter worries about valuation and the risk from lock-up expiry. Analysts point to SpaceX's strong position in launches and Starlink's global network, but note ongoing cash burn and no dividend. Some investors now look at the current price as a possible opportunity with index inclusion ahead as the next big event.
Go toTop